6,300 Shares in Zymeworks Inc. (NYSE:ZYME) Acquired by nVerses Capital LLC

nVerses Capital LLC acquired a new stake in Zymeworks Inc. (NYSE:ZYME) in the third quarter, HoldingsChannel.com reports. The firm acquired 6,300 shares of the company’s stock, valued at approximately $79,000.

Several other large investors have also modified their holdings of the company. Wellington Management Group LLP boosted its stake in shares of Zymeworks by 31.0% during the fourth quarter. Wellington Management Group LLP now owns 205,246 shares of the company’s stock worth $2,133,000 after buying an additional 48,564 shares during the period. AlphaMark Advisors LLC purchased a new position in shares of Zymeworks in the 1st quarter valued at approximately $32,000. Principal Financial Group Inc. acquired a new position in shares of Zymeworks in the first quarter valued at approximately $273,000. Empowered Funds LLC raised its stake in shares of Zymeworks by 8.2% during the first quarter. Empowered Funds LLC now owns 295,783 shares of the company’s stock worth $3,112,000 after purchasing an additional 22,367 shares during the last quarter. Finally, Swiss National Bank lifted its position in Zymeworks by 12.8% in the first quarter. Swiss National Bank now owns 83,000 shares of the company’s stock valued at $873,000 after purchasing an additional 9,400 shares during the period. 92.89% of the stock is owned by institutional investors and hedge funds.

Zymeworks Price Performance

NYSE ZYME opened at $13.48 on Monday. The business has a 50 day moving average price of $12.06 and a 200 day moving average price of $10.19. The company has a market capitalization of $957.75 million, a P/E ratio of -8.87 and a beta of 1.20. Zymeworks Inc. has a 1-year low of $6.51 and a 1-year high of $14.05.

Zymeworks (NYSE:ZYME) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. Zymeworks had a negative return on equity of 21.97% and a negative net margin of 179.42%. The business had revenue of $19.24 million during the quarter, compared to analysts’ expectations of $23.16 million. During the same quarter last year, the business posted ($0.76) earnings per share. On average, research analysts expect that Zymeworks Inc. will post -0.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. HC Wainwright increased their target price on Zymeworks from $10.00 to $12.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 25th. Stifel Nicolaus boosted their target price on shares of Zymeworks from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.